Thermo Fisher Scientific CD317 (BST2, PDCA-1) Monoclonal Antibody (eBio129c (129c)), APC, eBioscience

Applications and Tested Dilution

• Application: Flow Cytometry (Flow)
• Tested Dilution: 0.5 µg/test
• View 3 publications

Product Specifications

Additional Formats:

• Alexa Fluor 488
• PE
• Request custom conjugation

Product Specific Information

The eBio129c monoclonal antibody reacts with mouse PDCA-1 (BST2, CD317), a specific marker of plasmacytoid dendritic cells (pDC), also known as type I IFN-producing cells (IPC) in the naive mouse.
Mouse IPCs are typically CD11c+, CD11b-, B220+, Ly-6C+, and CD62L+. PDCA-1 is predominantly expressed by IPCs in the naive mouse, representing a minor population (<0.5%) of splenocytes. It is upregulated on numerous cell types following stimulation that triggers an IFN response. PDCA-1 cycles between cell surface and intracellular compartments and may regulate cytokine trafficking. PDCA-1 (BST2) is the protein recognized by the antibody 120G8.

The epitope recognized by eBio129c is distinct from eBio927; thus, both antibodies can be used to costain, purify, and identify pDCs.

Applications Reported:
This eBio129c (129c) antibody is reported for use in flow cytometric analysis.

Applications Tested:
Tested by flow cytometric analysis of mouse splenocytes. Recommended ≤0.5 µg per test (100 µL final volume). Cell number can range from 10⁵ to 10⁸ cells/test. Optimize titration for best performance.

Excitation: 633–647 nm
Emission: 660 nm
Laser: Red Laser
Filtration: 0.2 µm post-manufacturing filtered

Target Information

BST2 (CD317, HM1.24 antigen, DAMP-2, tetherin) is an integral membrane protein involved in B-cell development and growth. BST2 surface expression on fibroblast cell lines supports stromal cell-dependent growth of pre-B-cell lines.
It is highly expressed during B-cell development (from pro-B precursors to plasma cells), as well as in T-cells, monocytes, NK cells, DCs, and myeloma cells.

Research shows BST2 inhibits retrovirus release from human cells; its activity is counteracted by HIV-1 Vpu protein. Depletion of BST2 abolishes the viral requirement for Vpu, suggesting a potential therapeutic target for HIV/AIDS. BST2 dysfunction is also linked to stomatitis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

제품 이미지